Event-Driven Stocks

Stoke Therapeutics, Inc.

STOKNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$184.4M$36.6M$8.8M$12.4M——
Operating income−$20.6M−$101.4M−$114.8M−$104.4M−$86.1M−$53.0M
Net income−$6.9M−$89.0M−$104.7M−$101.1M−$85.8M−$52.2M
Total assets$418.4M$271.6M$228.3M$256.1M$238.9M$297.9M
Total liabilities$66.0M$42.5M$68.8M$71.2M$21.1M$11.8M
Equity$352.5M$229.0M$159.6M$184.8M$217.8M$286.1M
EPS (diluted)$-0.12$-1.65$-2.38$-2.60$-2.34—
Shares out.54.1M46.3M44.1M37.4M36.7M32.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−11.2%
Net margin
−3.7%
Return on equity
−2.0%
Return on assets
−1.6%
Return on capital (ROCE)
−5.7%
Liabilities / assets
15.8%
Debt / equity
0.19×
Book value / share
$6.52
Revenue growth (YoY)
404.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
5.29safe
Accruals / assets
−12.5%clean
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
73
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 5 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202612.9M24.8-0.8%
Apr 30, 202613.0M27.0+3.9%
Apr 15, 202612.5M20.8-2.2%
Mar 31, 202612.8M12.6-4.2%
Mar 13, 202613.4M14.5+7.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)